CHEK1 and head and neck squamous cell carcinoma: LY2606368/Prexasertib had no therapeutic window between primary cells and HNSCC cell lines, which might relate to dual Chk1/Chk2 inhibition or off-target effects as seen with other Chk1 inhibitors (Fig. 2b and S2e–g).